Pfizer Covers Its Dividend Better, but UPS Offers the Higher Yield

Pfizer and UPS both offer high yields with limited free-cash-flow cushions. Pfizer's payout is better covered, while UPS pays more and has stronger recent revenue growth after its Amazon network reset.
Pfizer and UPS offer unusually high dividend yields, but neither entered the second half of 2026 with a wide free-cash-flow cushion. The comparison is therefore less about choosing the biggest stated yield and more about deciding which set of business risks is easier to underwrite.
Using the source's trailing figures through June, Pfizer paid $9.79 billion in dividends against $10.98 billion of free cash flow, an 89% cash payout ratio. UPS paid dividends equal to about 99% of free cash flow. The lower ratio gives Pfizer more room today, although its patent expirations could pressure revenue through 2028. Management has emphasized maintaining the dividend, but maintenance is not the same as strong growth.
UPS offered the higher indicated yield in the comparison, 7.0% versus Pfizer's 6.3%. Its operating momentum was also stronger in the latest reported quarter: second-quarter revenue rose 7.6% to $22.8 billion after the company completed its reduction of lower-yield Amazon volume. Pfizer's second-quarter revenue rose 3% as reported and 1% operationally, while newer products partly offset declining COVID-related sales.
The trade-off is that UPS's dividend consumes nearly all current free cash flow. The company expects about $5.5 billion of free cash flow in 2026 and roughly $5.4 billion of dividends, subject to board approval. That leaves little protection against weaker volume, fuel costs or a slower margin recovery. Pfizer has a modestly better cash cushion, but its future coverage depends on replacing revenue lost to patent expiration.
A simple income projection can be misleading because it assumes dividend growth rates remain stable. UPS's payout per share rose only 0.6% in fiscal 2025, and Pfizer's payout has also been growing slowly. Investors should focus on free cash flow after capital spending and restructuring, not on a historical growth rate shaped by one large increase.
Pfizer currently offers better cash coverage. UPS offers more current income and a visible network-reset story. The deciding evidence will be whether Pfizer's new products replace lost exclusivity and whether UPS can rebuild free cash flow faster than its dividend obligation.
Continue your PFE research
Related News
Moderna's 6% Rally Had No New Company Announcement Behind It
Moderna outpaced biotech peers during an October 15 healthcare rally. The stock's stronger move may reflect enthusiasm for its cancer-vaccine program, but fuller trial data remains the next fundamental test.
Trump Media and Rumble Fell Faster Than the Market as Merger Risk Loomed
Trump Media dropped 6% and Rumble 8% during a broader selloff, highlighting their high volatility. For DJT, the pending TAE merger adds execution, dilution and fusion-development risk.
Carnival's Record 2027 Bookings Shift Attention to Pricing
Carnival reported record booked occupancy and pricing for 2027, supporting demand visibility after a strong share-price rebound. The next test is whether realized yields and costs preserve that advantage.
CoreWeave Credit Insurance Tops 1,000 Basis Points as Debt Fears Rise
CoreWeave's five-year credit-default swaps moved above 1,000 basis points while a 2031 bond yielded about 14.5%. Those market prices signal severe perceived credit risk even though the company continues to add long-term customer commitments.
Reddit's 61% Growth Supports Its Premium, but the Next Quarter Slows
Reddit's second-quarter revenue rose 61% and weekly active uniques reached 514.6 million, supporting a richer valuation than slower-growing peers. Management's third-quarter guide, however, implies a clear deceleration and leaves search traffic as a risk.
Disc Medicine's Phase 3 Win Clears the Clinical Bar, Not the FDA Bar
Bitopertin met both primary endpoints in Disc Medicine's pivotal APOLLO trial, strengthening its planned response to an earlier FDA rejection. The next value-driving step is regulatory acceptance, not another share-price reaction.













Latest comments